Cocrystal Pharma (COCP) Asset Utilization Ratio (2011 - 2026)

Cocrystal Pharma (COCP) reported Asset Utilization Ratio of 0.21 for Q1 2026, up 453.54% sequentially from 0.04 in Q4 2020.

Cocrystal Pharma (COCP) Asset Utilization Ratio (2011 - 2026) Analysis & Trends

Cocrystal Pharma (COCP) has 6 years of Asset Utilization Ratio data on file, last reported at 0.21 in Q1 2026.

For the quarter ending Q1 2026, Asset Utilization Ratio changed N/A year-over-year to 0.21; the trailing twelve-month figure through Mar 2026 stood at 0.21 (changed N/A YoY), and the FY2020 full-year result was 0.05, down 64.01% from the prior year.
Asset Utilization Ratio climbed to 0.21 in Q1 2026, from 0.04 in the prior quarter.
In the past five years, Asset Utilization Ratio ranged from a high of 0.21 in Q1 2026 to a low of 0.21 in Q1 2026.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	0.69
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	0.37
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Cocrystal Pharma	12.57 Mn	7.74 Mn	-	0.21

Historic Data

Download Data

Date	Value
Mar 31, 2026	0.21
Dec 31, 2020	0.04
Sep 30, 2020	0.04
Jun 30, 2020	0.05
Mar 31, 2020	0.05
Dec 31, 2019	0.13
Sep 30, 2019	0.08
Jun 30, 2019	0.08
Mar 31, 2019	0.07
Jun 30, 2013	1.68
Mar 31, 2013	2.19
Dec 31, 2012	2.22
Sep 30, 2012	1.96
Jun 30, 2012	1.88
Mar 31, 2012	1.76
Dec 31, 2011	1.42
Sep 30, 2011	1.23